Form 4: Abeona Therapeutics Executive Receives Stock Grant
SEC Form 4 Filing
Abeona Therapeutics' Senior Vice President and General Counsel, Brendan M. O'Malley, was granted 115,607 shares of restricted stock.
Summary
- Brendan M. O'Malley, Senior Vice President and General Counsel at Abeona Therapeutics, received a grant of 115,607 shares of common stock on January 21, 2025.
- The stock grant was awarded as restricted stock, meaning it will vest over a period of three years.
- One-third of the shares will vest on each of January 21, 2026, January 21, 2027, and January 21, 2028.
- Following this transaction, Mr. O'Malley beneficially owns 388,896 shares of Abeona Therapeutics common stock.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.
Positives
- The stock grant indicates a continued commitment to retaining key personnel.
- The vesting schedule aligns the executive's interests with the long-term performance of the company.
Industry Context
Stock grants are a common form of executive compensation in the biotechnology industry, often used to incentivize performance and align management interests with shareholder value.
Comparison to Industry Standards
- Stock grants are a standard practice for executive compensation across the biotechnology sector.
- Vesting schedules, such as the three-year plan outlined in this document, are typical to ensure long-term commitment from executives.
- Companies like BioMarin Pharmaceutical and Vertex Pharmaceuticals also use similar stock-based compensation plans for their executives.
Stakeholder Impact
- The stock grant may be viewed positively by shareholders as it incentivizes management to improve company performance.
- The vesting schedule ensures that the executive's interests are aligned with the long-term success of the company.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of the stock grant to Brendan M. O'Malley. |
| 01/23/2025 | Date the Form 4 was signed. |
| 01/21/2026 | First vesting date for one-third of the restricted stock. |
| 01/21/2027 | Second vesting date for one-third of the restricted stock. |
| 01/21/2028 | Final vesting date for one-third of the restricted stock. |
Keywords
stock grant, restricted stock, beneficial ownership, executive compensation, Abeona Therapeutics, ABEO, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.